The killer disease with no vaccine
By Dr Charlie Weller Head of
Vaccines, Wellcome Trust
- 5 March 2018
Since the beginning of the
year, Nigeria has been gripped by an outbreak of a deadly disease. Lassa fever
is one of a number of illnesses which can cause dangerous epidemics, but for
which no vaccine currently exists.
Lassa fever is not a new
disease, but the current outbreak is unprecedented, spreading faster and
further than ever before.
Health workers are
overstretched, and a number have themselves become infected and died.
The potentially fatal disease
is a so-called "viral haemorrhagic fever", which can affect many
organs, and damage the body's blood vessels.
But it is difficult to treat.
Most people who catch Lassa
will have only mild symptoms such as fever, headache and general weakness. They
may have none at all.
However, in severe cases, it
can mimic another deadly haemorrhagic fever, Ebola, causing bleeding through
the nose, mouth and other parts of the body.
Lassa fever normally has a fatality rate of about
one per cent. But in the Nigerian outbreak it is thought to be more than 20% among
confirmed and probable cases, according to the country's Centre for Disease Control.
Lassa fever outbreak in Nigeria
22%
fatality rate
- 1081 suspected cases (1 January - 25 February)
- 317 confirmed cases
- 14 health care workers affected in six states
Nigeria Centre for Disease
Control
Getty
About 90 people are thought to
have died so far, but the true number may be much higher, because Lassa is so
hard to diagnose.
Women who contract the disease
late in pregnancy face an 80% chance of losing their child, or dying
themselves.
In the early stages it's
almost impossible to distinguish from other common diseases like malaria and
dengue.
With no readily available
test, the only way to confirm a diagnosis is to analyse a blood or tissue
sample in one of small number of specialised laboratories.
The disease was first
identified in the Nigerian town of Lassa in 1969, after an outbreak in a
mission hospital.
It has since been seen in many
West African countries including Ghana, Mali and Sierra Leone.
Multimammate rodents spread Lassa virus via their urine
and droppings
However, this outbreak is
causing particular concern because the number of cases is unusually high for
the time of year.
Health officials are working
to understand why.
Outbreaks can be influenced by
seasonal weather conditions, which affect the numbers of the virus's natural
host - the multimammate rat.
These small mammals are common
across West Africa, where they easily find their way into homes.
Another possibility is that
the high number of cases reflects heightened public awareness.
Or it's possible that
something about the virus has changed.
Most people catch Lassa fever
from anything contaminated with rat urine, faeces, blood or saliva - through
eating, drinking or simply handling contaminated objects in the home.
Authorities have banned the consumption of raw garri, a popular
Nigerian food, which it says can spread Lassa fever
It can also pass from person
to person through bodily fluids, meaning healthcare workers and people taking
care of sick relatives without protective equipment are particularly at risk.
The incubation period for
Lassa is up to three weeks. Researchers are trying to work out whether - like
Ebola - Lassa can stay in the body and be passed on through sexual contact even
after illness subsides.
Nigeria has a strong public
health system, and is used to dealing with epidemics like this.
The World Health Organization
(WHO) is working with Nigerian authorities to help coordinate the response and the UK government has
deployed a team of experts from its Public Health Rapid Support Team.
Those living in affected areas
are being advised to take basic precautions: blocking holes that may allow rats
to enter their homes, disposing of rubbish in covered dustbins, and storing
food and water in sealed containers.
People are advised to wear
protective gloves when caring for anyone who may have Lassa fever, and to carry
out safe burial practices.
Despite these measures, the
fight against Lassa - and other infectious diseases - is hampered by a lack of
effective medical tools like diagnostic tests, treatments and vaccines.
It is likely that a vaccine
could be found for Lassa - reducing the possibility of an outbreak becoming a
global health emergency - but as with other epidemic diseases that mainly
affect poorer countries, progress has stalled.
Vaccine development is a long,
complex and costly process. This is especially true for emerging epidemic
diseases, where a prototype vaccine can usually only be tested where there is
an outbreak.
A new organisation called CEPI (Coalition for Epidemic Preparedness Innovations) - set up in 2017 with
financial support from the Wellcome Trust, national governments and the Bill
& Melinda Gates Foundation - hopes to accelerate vaccine production.
Lassa is one of the
diseases on its hit list and it's hoped one or more promising vaccines will be ready for
large-scale testing in the next five years.
Ebola claimed more than 11,000 lives across West Africa in the
2014-2015 outbreak
The WHO has drawn up a list of
other serious, but often poorly understood diseases, with the potential for
devastating outbreaks, including MERS, Nipah, Rift Valley Fever and, of course,
Ebola.
It plans to highlight gaps in
our knowledge of these diseases and to begin further research.
But research alone isn't
enough.
Stronger health systems are
needed in the countries where epidemics are most likely to arise.
This could mean building
better healthcare facilities and training staff to recognise and respond to
outbreaks.
It will also mean working with
communities to understand how to identify outbreaks at an early stage and
prevent their spread.
About this piece
This analysis piece was
commissioned by the BBC from an expert working for an outside organisation.
Dr Charlie Weller is head of
vaccines at the Wellcome Trust, which describes itself as a
global charitable foundation working to improve health for everyone. Follow her at @DrCharlieWeller.
Edited by Jennifer Clarke.
Aucun commentaire:
Enregistrer un commentaire